Aspira Women’s Health (NASDAQ:AWH – Get Rating) was downgraded by equities researchers at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research note issued to investors on Friday, The Fly reports.
→ Laser breakthrough could send stock soaring 2,476% (From Behind the Markets)
Separately, StockNews.com initiated coverage on shares of Aspira Women’s Health in a report on Monday, December 12th. They set a “sell” rating for the company.
Aspira Women’s Health Price Performance
Shares of Aspira Women’s Health stock opened at $0.50 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.11 and a current ratio of 3.15. The firm’s 50-day simple moving average is $0.37 and its 200-day simple moving average is $0.37. Aspira Women’s Health has a twelve month low of $0.29 and a twelve month high of $1.34. The firm has a market cap of $62.30 million, a P/E ratio of -1.85 and a beta of 2.69.
Aspira Women’s Health (NASDAQ:AWH – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. Aspira Women’s Health had a negative net margin of 393.68% and a negative return on equity of 160.74%. The firm had revenue of $2.07 million during the quarter, compared to the consensus estimate of $2.40 million. As a group, research analysts expect that Aspira Women’s Health will post -0.29 EPS for the current fiscal year.
Hedge Funds Weigh In On Aspira Women’s Health
A number of institutional investors have recently modified their holdings of AWH. JPMorgan Chase & Co. raised its stake in shares of Aspira Women’s Health by 126.3% in the first quarter. JPMorgan Chase & Co. now owns 64,839 shares of the company’s stock worth $67,000 after acquiring an additional 36,189 shares during the last quarter. Private Advisor Group LLC raised its stake in shares of Aspira Women’s Health by 361.8% during the first quarter. Private Advisor Group LLC now owns 69,697 shares of the company’s stock worth $73,000 after buying an additional 54,603 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Aspira Women’s Health by 5.7% during the first quarter. Vanguard Group Inc. now owns 3,067,896 shares of the company’s stock worth $3,191,000 after buying an additional 164,635 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Aspira Women’s Health by 18.5% during the first quarter. Renaissance Technologies LLC now owns 1,132,801 shares of the company’s stock worth $1,178,000 after buying an additional 177,075 shares during the last quarter. Finally, Atria Wealth Solutions Inc. bought a new stake in shares of Aspira Women’s Health during the first quarter worth approximately $49,000. 10.63% of the stock is owned by institutional investors.
About Aspira Women’s Health
Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aspira Women’s Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aspira Women’s Health wasn’t on the list.
While Aspira Women’s Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
